In this era of personalized medicine, biomarkers can provide important insights at every stage of drug discovery and development. By advancing our understanding of cancer pathophysiology and tumor profiling, they play a critical role in the rational development of novel therapies.
Despite their many potential advantages, biomarker development and biomarker-guided trials can be complex and costly. With thorough planning and clarity around the overall objective, however, these trials promise to deliver better outcomes for patients in need of life-changing therapies.
Webinar topics will include:
- The evolution of biomarker-guided oncology trials
- Driving smarter study design: Enhancing efficacy through biomarker-matched trials
- Data considerations and limitations: The impact of next-generation sequencing, access to data, and challenges with global trial execution
- What’s next for precision oncology and where biomarkers are heading
Speakers:
Rupa Doshi, Ph.D.
Vice President, Oncology Strategy
Ashley Herrick, Ph.D.
Executive Director, Oncology Program Strategy